Clinical indication of anti-PD-1/anti-PD-L1 antibody for breast cancer

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K18062
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: University of Yamanashi (2020-2021); Fukushima Medical University (2019)
• Principal Investigator: Nakayama Yuko 山梨大学, 大学院総合研究部, 助教 (90769001)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 乳癌 / PD-L1 / 浸潤性小葉癌 / EMT

Outline of Final Research Achievements

We examined the efficacy of anti-PD-1/anti-PD-L1 antibodies in breast cancer. The subjects were invasive ductal carcinoma of the breast and invasive lobular carcinoma, and the tumor microenvironment was verified, but the number of cases of invasive lobular carcinoma was small and insufficient for the verification. In addition, the antibodies used were different from the anti-PD-1/anti-PD-L1 antibodies indicated for breast cancer, necessitating a review of the research strategy. Therefore, we were unable to present sufficient results.

Free Research Field

乳腺外科

Academic Significance and Societal Importance of the Research Achievements

浸潤性乳管癌と浸潤性小葉癌を対象に腫瘍微小環境について比較し、PD-L1の発現について違いがあるか検証した。浸潤性小葉癌とPD-L1の発現に強い相関があり、抗PD-1/抗PD-L1抗体が有効である腫瘍微小環境が整っていれば、浸潤性小葉癌の新たな治療戦略として免疫チェックポイント阻害薬が候補となる可能性があった。